Skip to main content
OpenTrials
Completed

NCT Number: NCT00509717

Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs

The purpose of this study is to determine the effectiveness of maximal support of community pharmacies to implement a pharmaceutical care model for improving underprescription and treatment persistence regarding lipid-lowering medication in patients with cardiovascular disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiovascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

UMC St Radboud, Scientific Institute for Quality of Healthcare

Nijmegen, NL, 6500 HB, Netherlands

About this study

Cardiovascular disease is the main cause of death in large parts of the world. Next to life style changes, pharmaceutical treatment is a keystone in the treatment of cardiovascular disease. Despite the strong evidence for the effectiveness of lipid-lowering therapy, less than half of the people eligible are treated. With specific medication searches in the community pharmacy database, an easy tool for detecting patients who are undertreated is available. Based on this tool, a pharmaceutical care model for improving underprescription and treatment persistence regarding lipid-lowering medication in patients with cardiovascular disease was constructed.

Moreover, it is not known yet how to implement this pharmaceutical care model in community pharmacies effectively. With multifaceted interventions the behaviour of health professionals can be changed. In this study the effectiveness of a maximal support strategy, including interactive educational meetings, reminders, audit and feedback, is compared to a minimal implementation strategy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • pharmacies: resident in the south of the Netherlands
  • patients: with antiplatelet therapy and without lipid-lowering medication

Exclusion criteria

for patients:

  • terminal disease
  • severe mental disorder

Treatment and study plan

intensive implementation programme

Other

educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.

Control

Other

educational manual

Primary outcomes

  1. The percentage of selected (=undertreated) patients receiving at least one prescription for lipid-lowering medication.

    Time frame: six months after the general practitioner received the list with selected patients

Secondary outcomes

  1. Differences in prescribing for age categories and co-medication.

    Time frame: six months

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Collaborators

  • Scientific Institute for Dutch Pharmacists, The Netherlands
  • Zorgverzekeraar CZ

Registry information

Official study title

Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs. A Randomized Trial.

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Jul 31, 2007
Registry last updated
Jul 10, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.